A change of tone from the US authorities has introduced new uncertainties. Under health secretary and outspoken vaccine ...

Some of the top-grossing drugs include Merck's Keytruda, an immunotherapy for multiple cancers with almost $30 billion in ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of ...

U.S. biotech share sales deliver biggest first week since 2021; President Trump claims he'll unveil long-awaited framework ...

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales ...

Strong domestic sales are expected to lift Q3FY26 pharma revenues by 8-11%, while US generic Revlimid impacts weigh on margins. Hospitals and diagnostics outperform, with 20-22% revenue growth ...

BAYRY jumps 6.6% after partner Orion said Nubeqa sales tied to Bayer could top ???1B long term. Bayer also announced pharma ...

2025 might shape out to be a boon year for pharma, a recent report from Norstella’s Evaluate suggests. The 2025 Preview Report examines the “biggest movers and shakers” in the biotech and pharma ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. Nevertheless, at least as far as ...

Andy Timmerwilke is a Managing Director at Merrill (Bank of America) in Chicago advising high‑net‑worth families, executives, ...